NDAINTRAVENOUSSOLUTION
Approved
Apr 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Mechanism of Action
[see Microbiology ()].
Indications (22)
older) for the treatment of Community Acquired Pneumonia caused by susceptible isolates of Streptococcus pneumoniae (including multi-drug resistant isolates*)Haemophilus influenzaeMoraxella catarrhalismethicillin-susceptible Staphylococcus aureusKlebsiella pneumoniaeMycoplasma pneumoniaeChlamydophila pneumoniaeolder) for the treatment of Uncomplicated SkinSkin Structure Infections caused by susceptible isolates of methicillin-susceptible Staphylococcus aureusolder) for the treatment of Complicated SkinEscherichia coliolder) for the treatment of Complicated Intra-Abdominal Infections including polymicrobial infections suchBacteroides fragilisStreptococcus anginosusStreptococcus constellatusEnterococcus faecalisProteus mirabilisClostridium perfringensBacteroides thetaiotaomicronolder) for the treatment of Acute Bacterial Sinusitis (ABS) caused by susceptible isolates of Streptococcus pneumoniaeolder) for the treatment of Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) caused by susceptible isolates of Streptococcus pneumoniaeHaemophilus parainfluenzae
Clinical Trials (1)
Effectiveness and Safety of 0.5% Moxifloxacin Hydrochloride Ophthalmic Solution in Perioperative Sterilization in Patients Undergoing Ophthalmic Surgery
Started Jan 2024
102 enrolled
Post Operative Endophthalmitis